Exacerbation of juvenile myoclonic epilepsy with lamotrigine

Abstract

The efficacy and safety of lamotrigine (LTG) (Lamictal; Glaxo-Wellcome Laboratories, Research Triangle Park, NC) are documented in different types of epileptic seizures and syndromes, notably in idiopathic generalized epilepsies. In the case of childhood and juvenile absence epilepsies, this drug is effective when given in cotherapy with valproic acid (resistant forms) or as substitution therapy when valproic acid is poorly tolerated.1-3⇓⇓ The same therapeutic strategy could be proposed, …